Greenwood Diagnostic Laboratories in partnership with London Health Science Centre present EpiSign!
EpiSign is an assay designed to readily identify proven and reproducible epigenetic signatures by assessing genome-wide methylation.
EpiSign has multiple applications in the clinical setting by providing an additional diagnostic tool beyond the current sequencing and copy number technology paradigm. EpiSign can detect multiple methylation abnormalities associated with certain imprinting or triplet repeat conditions. This test can also identify disease-specific methylation patterns involving multiple loci across the genome.
Assessment of these distinct methylation patterns can be a useful screening tool for these disorders in the diagnostic work-up or can be applied in a more targeted fashion to help resolve variants of uncertain clinical significance.
Version 4 launched February 2023 increasing the number to more than 70 identifiable disorders.
One Assay. Two Options.
Episign is offered as two different tests to suit the needs of your patient.
We will remember February 26th for the rest of our lives.
On that day, we received the call from the Greenwood Genetic Center that they had discovered our daughter, Ella Marie, has Kleefstra syndrome.
Very early on, my wife, Kelly, observed Ella being delayed in some of her milestones. Kelly monitored Ella’s progression and sought out testing in an effort to get Ella some assistance. Along the way, we were sent to GGC and met with Dr. Roger St...